BioSpace News Archive

Silq Technologies, a leader in advanced biomaterial science, has been selected to exhibit its novel ClearTract™ indwelling Foley catheter at the upcoming Vizient Innovative Technology Exchange.

ReCode Therapeutics today announced that Company management will participate in the following upcoming investor conferences in September 2023.

Thermo Fisher Scientific Inc., the world leader in serving science, and the National Minority Quality Forum, an independent not-for-profit research and education organization, announced a collaboration to help bring clinical research to historically underserved patient populations through NMQF’s Alliance for Representative Clinical Trials.

Geron Corporation (Nasdaq: GERN) today announced poster presentations of data from IMerge, the Company’s Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat vs. placebo in patients with lower risk myelodysplastic syndromes (MDS) at the eleventh annual Society of Hematologic Oncology Annual Meeting (SOHO) held in Houston, Texas and virtually.

CUTERA, INC. a global leader in aesthetic and dermatology solutions, announces the launch of Secret DUO, an innovative skin resurfacing and revitalization platform that utilizes dual non-ablative fractional technologies.

Noetik , an AI drug discovery company leveraging machine learning and proprietary human data to develop precision therapeutics in immuno-oncology, announced today that it closed an oversubscribed $14M seed financing round led by DCVC.

Rapport Therapeutics, Inc today announced the appointment of Cheryl Gault as Chief Operating Officer and Wendy Young, Ph.D., as a member of its Scientific Advisory Board.

Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2023, at the Lotte New York Palace Hotel.

CRISPR Therapeutics announced that Rodger Novak, M.D., President and Chairman of the Board of CRISPR Therapeutics, has elected to leave CRISPR Therapeutics after nearly a decade of dedicated service to the Company.

Simulations Plus, Inc. announced the successful completion of the inaugural University+ PBPK Summer Camp, an intensive eight-week course covering the theory and application of PBPK modeling using GastroPlus ® .